Progress in Clinical Research on Drug Resistance and Reversal of Endocrine Therapy in Breast Cancer

Wen-jing SUN; Man-ting HU; Na LI; Fei GE; Wen-lin CHEN; Yang LIU

doi:10.12259/j.issn.2095-610X.S20210724

Volume 42 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(7): 143-149

Wen-jing SUN, Man-ting HU, Na LI, Fei GE, Wen-lin CHEN, Yang LIU. Progress in Clinical Research on Drug Resistance and Reversal of Endocrine Therapy in Breast Cancer[J]. Journal of Kunming Medical University, 2021, 42(7): 143-149. doi: 10.12259/j.issn.2095-610X.S20210724

Citation:

Wen-jing SUN, Man-ting HU, Na LI, Fei GE, Wen-lin CHEN, Yang LIU. Progress in Clinical Research on Drug Resistance and Reversal of Endocrine Therapy in Breast Cancer[J]. Journal of Kunming Medical University, 2021, 42(7): 143-149. doi: 10.12259/j.issn.2095-610X.S20210724

Citation:

PDF( 675 KB)

Progress in Clinical Research on Drug Resistance and Reversal of Endocrine Therapy in Breast Cancer

doi: 10.12259/j.issn.2095-610X.S20210724

1.
NO 1 Department of Breast Surgery，The Third Affiliated Hospital of Kunming Medical University，Yunnan Cancer Hospital，Kunming Yunnan 650118
2.
Dept. of Breast Surgery，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2021-05-09
Available Online: 2021-07-19
Publish Date: 2021-07-21

Abstract

Abstract

In the initial stage of clinical treatment of hormone receptor positive HR + breast cancer, good prognosis is often achieved by endocrine therapy. Once recurrence and metastasis occur, the overall prognosis is not ideal. Therefore, the efficacy of endocrine therapy is limited by the emergence of drug resistance these years. The reversal of endocrine resistance is considered to be a new method and hope for early hormone receptor positive breast cancer to return to chronic disease treatment. The strategy of delaying and reversing endocrine drug resistance has been paid close attention by clinical and scientific research work. This article will review the research progress and strategies of delaying and reversing endocrine therapy.
- Breast cancer,
- Endocrine therapy,
- Drug resistance,
- Reversal

FullText(HTML)

References(24)

References

[1]	Wu Y L,Zhang L,Kim D W,et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer[J]. J Clin Oncol,2018,36(31):3101-3109.
[2]	Osborne C K,Neven P,Dirix L Y,et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer:a randomized phase II study[J]. Clin Cancer Res,2011,17(5):1147-1159. doi: 10.1158/1078-0432.CCR-10-1869
[3]	Kaufman B,Mackey J R,Clemens M R,et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase III TAnDEM study[J]. J Clin Oncol,2009,27(33):5529-5537. doi: 10.1200/JCO.2008.20.6847
[4]	Rugo H S, Im S A, Cardoso F, et al. Efficacy of Margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial[J]. JAMA Oncol,2021,7(4):573-584.
[5]	Carlson R W,O’Neill A,Vidaurre T,et al. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer[J]. Breast Cancer Res Treat,2012,133(3):1049-1056. doi: 10.1007/s10549-012-1997-5
[6]	Li Y,Guo Q,Zhang C,Huang Z,et al. Discovery of a highly potent,selective and novel CDK9 inhibitor as an anticancer drug candidate[J]. Bioorg Med Chem Lett,2017,27(15):3231-3237. doi: 10.1016/j.bmcl.2017.06.041
[7]	Johnston S,Martin M,Di Leo A,et al. MONARCH 3 final PFS:a randomized study of abemaciclib as initial therapy for advanced breast cancer[J]. NPJ Breast Cancer,2019,5:5. doi: 10.1038/s41523-018-0097-z
[8]	Malorni L,Curigliano G,Minisini A M,et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive,HER2-negative metastatic breast cancer:TREnd trial[J]. Ann Oncol,2018,29(8):1748-1754. doi: 10.1093/annonc/mdy214
[9]	Hortobagyi G N,Stemmer S M,Burris H A,et al. Updated results from MONALEESA-2,a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive,HER2-negative advanced breast cancer[J]. Ann Oncol,2018,29(7):1541-1547. doi: 10.1093/annonc/mdy155
[10]	Baselga J,Im S A,Iwata H,et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal,hormone receptor-positive,HER2-negative,advanced breast cancer(BELLE-2):A randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncol,2017,18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5
[11]	Krop I E,Mayer I A,Ganju V,et al. Pictilisib for oestrogen receptor-positive,aromatase inhibitor-resistant,advanced or metastatic breast cancer(FERGI):a randomised,double-blind,placebo-controlled,phase 2 trial[J]. Lancet Oncol,2016,17(6):811-821. doi: 10.1016/S1470-2045(16)00106-6
[12]	Mayer I A,Abramson V G,Formisano L,et al. A phase Ib study of alpelisib(BYL719),a PI3Kalpha-specific inhibitor,with letrozole in ER+/HER2- metastatic breast cancer[J]. Clin Cancer Res,2017,23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134
[13]	Hortobagyi G N,Chen D,Piccart M,et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:Results from BOLERO-2[J]. J Clin Oncol,2016,34(5):419-426. doi: 10.1200/JCO.2014.60.1971
[14]	Ma C X,Sanchez C,Gao F,et al. A Phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer[J]. Clin Cancer Res,2016,22(11):2650-2658. doi: 10.1158/1078-0432.CCR-15-2160
[15]	Kim H J,Kwon H,Lee J W,et al. Metformin increases survival in hormone receptor-positive,HER2-positive breast cancer patients with diabetes[J]. Breast Cancer Res,2015,17(1):64. doi: 10.1186/s13058-015-0574-3
[16]	Sonnenblick A,Agbor-Tarh D,Bradbury I,et al. Impact of diabetes,insulin,and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer:Analysis from the ALTTO phase III randomized trial[J]. J Clin Oncol,2017,35(13):1421-1429. doi: 10.1200/JCO.2016.69.7722
[17]	Goedert J J,Hua X,Bielecka A,et al. Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota[J]. Br J Cancer,2018,118(4):471-479. doi: 10.1038/bjc.2017.435
[18]	Hou X,Huang F,Macedo L F,et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer[J]. Cancer Res,2011,71(24):7597-7607. doi: 10.1158/0008-5472.CAN-11-1080
[19]	Tamura K,Tsurutani J,Takahashi S,et al. Trastuzumab deruxtecan(DS-8201a)in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine:a dose-expansion,phase 1 study[J]. Lancet Oncol,2019,20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X
[20]	Toy W,Shen Y,Won H,et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genet,2013,45(12):1439-1445. doi: 10.1038/ng.2822
[21]	Puyang X,Furman C,Zheng G Z,et al. Discovery of selective estrogen receptor covalent antagonists for the treatment of ERα WT and ERα MUT breast cancer[J]. Cancer Discovery,2018,8(9):1176-1193. doi: 10.1158/2159-8290.CD-17-1229
[22]	Piggott L,Silva A,Robinson T,et al. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP[J]. Clin Cancer Res,2018,24(10):2452-2463. doi: 10.1158/1078-0432.CCR-17-1381
[23]	Malorni L,Biagioni C,Luca F D,et al. Abstract 4416:Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial[J]. Cancer Research,2019,79(9):4416-4416.
[24]	Demark-Wahnefried W,Schmitz K H,Alfano C M,et al. Weight management and physical activity throughout the cancer care continuum[J]. CA Cancer J Clin,2018,68(1):64-89. doi: 10.3322/caac.21441

Relative Articles(20)

Relative Articles

[1]	Zheng ZHANG, Yanhong YANG, Zaihui FENG, Lujiang ZHAN, Jinxian PU, Qianting DUAN. Value of High Field Tntensity MRIT1 Perfusion Imaging Combined with DWI Imaging in Evaluating The Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Journal of Kunming Medical University, 2024, 45(7): 148-153. doi: 10.12259/j.issn.2095-610X.S20240722
[2]	Mei YAN, Qiongyao GUAN, Yuanxiao WANG, Liqi GU, Lei ZHE, Lijuan LIU, Runzhen HAO, Yan SU, Sisi HUANG. Association between Unmet Needs and Dyadic Coping of Breast Cancer Patients and Spouses after Radical Mastectomy. Journal of Kunming Medical University, 2023, 44(4): 93-99. doi: 10.12259/j.issn.2095-610X.S20230410
[3]	Tao HU, Yi WU, Wenda GENG, Yijian ZHANG, Xuan HE, Shanshan LI, Yanbin XIYANG, Liling DENG. Voluntary Exercise Training Attenuated the Proliferation and Growth of Human Breast Cancer with BRCA1 Mutation by Regulating Caspase-3 Activity. Journal of Kunming Medical University, 2023, 44(4): 31-39. doi: 10.12259/j.issn.2095-610X.S20230419
[4]	Jing LIU, Mei YAN, Yashuang CHEN, Liyu DU, Sisi HUANG. Survey and Analysis of Supportive Care Needs of Patients after Radical Breast Cancer Surgery based on Kano Model. Journal of Kunming Medical University, 2023, 44(11): 188-194. doi: 10.12259/j.issn.2095-610X.S20231129
[5]	Shi CHEN, Shi FU, Zhiyong TAN, Jiansong WANG, Haifeng WANG. Research Progress of Autophagy in the Development and Treatment of Bladder Cancer. Journal of Kunming Medical University, 2023, 44(5): 168-174. doi: 10.12259/j.issn.2095-610X.S20230503
[6]	Xiaomei JIN, Jieyan HE, Jichang SHI, Hui XING, Hong WANG, Ju ZHANG, Lijuan DONG, Lihua HUANG, Min CHEN, Zhijuan CHEN, Huichao CHEN. Virus Genotypes and Drug Resistance among HIV/AIDS Patients before Antiretroviral Therapy in Dali Bai Autonomous Prefecture in 2018. Journal of Kunming Medical University, 2023, 44(11): 152-157. doi: 10.12259/j.issn.2095-610X.S20231123
[7]	Wenjuan SONG, Xuejuan MA, Yue SUN, Ying GU, Yujia YE, Shumo LI, Fei GE, Liping LIU, Yue ZHAO, Yu WANG. Evaluation of Cardiotoxicity in Trastuzumab Treatment of Breast Cancer Using Three-dimensional Speckle Tracking Echocardiography. Journal of Kunming Medical University, 2023, 44(2): 108-112. doi: 10.12259/j.issn.2095-610X.S20230217
[8]	Chenxi LI, Zhuocen ZHA, Na LI, Lin LUO, Yang YANG, Wenlin CHEN. Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer. Journal of Kunming Medical University, 2023, 44(10): 180-188. doi: 10.12259/j.issn.2095-610X.S20231020
[9]	Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer. Journal of Kunming Medical University, 2023, 44(12): 46-50. doi: 10.12259/j.issn.2095-610X.S20231208
[10]	Siqi XIE, Hengyu ZHANG, Hongwan LI, Mingjian TAN, Qing WANG, Sijia LI, Kai ZHENG, Dequan LIU, Shicong TANG. Correlation between Serum Valine and Methionine Levels and Clinical Features and Risk of Breast Cancer. Journal of Kunming Medical University, 2022, 43(8): 47-55. doi: 10.12259/j.issn.2095-610X.S20220807
[11]	Jiang ZHANG, Yan LIU, Wen-hui LI, Xi-juan ZHAO, Zheng-ting CHEN, Qiong-yao GUAN, Jiang WU. Effects of Pre-sleep Music Therapy on Sleep Quality and Cancer-related Fatigue in Patients with Breast Cancer Undergoing Radiotherapy. Journal of Kunming Medical University, 2020, 41(12): 173-178. doi: 10.12259/j.issn.2095-610X.S20201248
[12]	Duan Jia Jun , Liu De Quan , Zhang Yong . . Journal of Kunming Medical University, 2019, 40(05): 37-41.
[13]	Li Ning , Xu Miao , Zhang Wei , Zhang Qing , Kong Ying . Clinical Significance of Serum Vitamin D Levels Change in Patients with Breast Cancer before and after Chemoradiotherapy. Journal of Kunming Medical University, 2018, 39(08): 108-112.
[14]	Zhang Yan Ye , Li Rong Qing , Zhang Yong . . Journal of Kunming Medical University, 2018, 39(11): 124-130.
[15]	Zhao Yun Hong , Fu Da Gan , Tang Yi Yin , Hao Fang , Shi Qiao Ming , Zhang Li Juan . . Journal of Kunming Medical University, 2017, 38(03): 51-54.
[16]	Wang Yi Ming , Yang Yue . Comparison of the Diagnosis Significance for Breast Cancer between Single High Frequency Ultrasonography and Mammography. Journal of Kunming Medical University, 2017, 38(06): 48-51.
[17]	Li Yun Fen . . Journal of Kunming Medical University,
[18]	Li Xiao Yong . . Journal of Kunming Medical University,
[19]	Zhao Chun Fang . . Journal of Kunming Medical University, 2013, 34(01): 1-1.
[20]	Li Kun Lun . Effect of Survivin Gene Expression Inhibition by RNAi on Breast Cancer SKBr-3 Cells. Journal of Kunming Medical University,